Novel vehicle contributes to cyclosporine efficacy

Special to Ophthalmology Times®

Topical cyclosporine A (CsA) has long been a mainstay of treatment for dry eye disease. In fact, for many years, CsA 0.05% (Restasis, Allergan) was the only treatment available to our patients, other than steroids or palliative artificial lubricants.

More recently, we have seen the introduction of lifitegrast 5% (Xiidra, Novartis), multiple treatments for underlying meibomian gland dysfunction, and higher-concentration CsA formulations (Cequa, Sun Pharmaceutical Industries; and Klarity-C, ImprimisRx) for a more robust armamentarium of treatment options for dry eye disease.

Related: Boosting short-term dry eye management in patients​

CsA is an immunosuppressant that inhibits T-cell–mediated inflammation and cytokines, stimulates tear production, and increases goblet cell density.^1,2

Despite its success in the marketplace and in many of our practices, there are still challenges with its use, including the high cost of the prescription solution for patients and burning or stinging on instillation, which can discourage patients from continuing the drops long enough to see an effect.

Additionally, it is challenging to formulate a topical CsA preparation because this molecule is not very water soluble.

I have been involved in a study to evaluate efficacy in a real-world clinical practice setting of a higher-dose (0.1%) cyclosporine (Klarity-C) in a unique chondroitin sulfate formulation.3 

Chondroitin sulfate, a compound developed decades ago by Richard Lindstrom, MD, Herbert Kaufman, MD, and others, is the key ingredient in OptiSol-GS (Bausch + Lomb) and is used in several viscoelastic products. It has some unique properties of its own, including lubricating, anti-inflammatory, cell membrane stabilizing, and corneal edema reducing.⁴

Related:As cyclosporine options grow, focus remains on the vehicle​

Klarity-C, the drug used in our study, is a preservative-free drop compounded in a 503B FDA-regulated outsourcing facility. 503B pharmacies have to follow stringent quality and manufacturing requirements and are subject to the same FDA inspection and oversight as large pharmaceutical companies.

However, compounded medications are typically more affordable than other branded drugs.

Study design and results
This was a retrospective, multicenter study conducted by me, Jennifer Loh, MD, and William Trattler, MD.

Adult patients with a dry eye diagnosis who were treated with Klarity-C twice daily were included. We reviewed patients’ charts to determine the change from baseline in Ocular Surface Disease Index (OSDI) scores and corneal staining after 3 months of treatment.

Fifty-one patients with dry eye (102 eyes) were enrolled. Patients ranged in age from 27 to 80 years, with a mean age of 62 years, and 76% were women.

The OSDI questionnaire measures dry eye symptoms, including visual symptoms and ocular discomfort. Patients are asked to select if they experienced any of the 12 symptoms all, most, half, some, or none of the time during the previous week, and the answers are scored from 0 to 100, with a lower score being ideal.

At 3 months, our patients’ mean OSDI score improved from 37.57 to 23.83 (P < .001). Pretreatment, 61% of the patients had OSDI scores in the “severe” range (33-100).

Related: As cyclosporine options grow, focus remains on the vehicle​

By 3 months, patients scoring in the severe range declined to 20%, and more than one-third of patients reported improvements in symptoms that put them in the normal (0-12) range.

Fluorescein staining of the entire cornea was evaluated for each eye (N = 102). The mean staining grade improved from 3.57 pretreatment to 2.17 (P < .001) at 3 months.

I find corneal staining with vital dyes to be an excellent diagnostic tool. In the PHACO study, Trattler et al showed that staining is extremely common in older patients, with 77% of those presenting for cataract surgery demonstrating some corneal staining (central or peripheral), including 50% with central staining.⁵ 

Internal server error